



NEPHROLOGY  
PHRAMONGKUTKLAO HOSPITAL



# Hypertension for medical student

**Jiranat Sriswasdi, M.D.**

**Division of Nephrology**

**Department of Medicine Phramongkutklao Hospital**

**25/5/2026**

# Outline

- **Epidemiology**
- **Pathophysiology**
- **Definitions**
- **Causes & Risk factor**
- **Hypertension mediated organ damages**
- **BP measurement & assessment**
- **Treatment**

# Pre-test

- A 50-year-old man, routine check up, has office BP reading of 160/90 mmHg, physical examination is unremarkable as other laboratory investigation. His home blood pressure is 138/80 mmHg.
- What is the diagnosis?


- A) Essential Hypertension
- B) Blood pressure at risk
- C) Isolated systolic hypertension
- D) White coat hypertension
- E) Masked hypertension

# Pre-test

- **A 70-year-old man, with history of recurrent hospitalization for heart failure for recent year. Current medications are enalapril, hydrochlorothiazide, amlodipine, all are in maximum dose. Blood pressure is 180/100 mmHg which had been controlled in 5 years of HT diagnosis.**
- **What is the most appropriate investigation?**

- **A) Plasma aldosterone, renin activity**
- **B) Renal doppler ultrasound**
- **C) Thyroid function test**
- **D) Polysomnography**
- **E) 24h-urine fractionated metanephrine**

# Epidemiology: prevalence of HT




- In Thailand (2024-2025 data)
  - Age  $\geq 15$  years, prevalence = **29.5%**
  - 3.8% in 15-29 years
  - 76.8% in  $\geq 80$  years
  - North-East 33.8%, North 34.2%
  - Undiagnosed **47.8%**
  - Well controlled **23.8%**

# Epidemiology: outcomes of HT

Every  $\Delta$ SBP  $\uparrow$  20 mmHg  
CV death  $\uparrow$  33-51%

Major causes of HF,  
AF, CAD, PAD

Second most  
common cause  
of CKD/ESKD




Dominant cause of stroke  
(77% in 1<sup>st</sup> diagnosis)

$\uparrow$  Incidence of  
dementia

Associated  
with all-cause  
death 14%

# Blood pressure in vascular beds




Focusing on *large* arteries pressure

- Easily measured
- Determines organ perfusion

If too low (shock) → ↓ organ perfusion  
If too high (*hypertension*) → *acute & chronic damage*

# Autoregulation: local organ regulation




**Autoregulation of blood flow**

- Organs (i.e., **brain/kidney**) try to maintain **constant blood flow** (perfusion) despite wide range of systemic blood pressure
- **Local** vasodilation if ↓BP
- **Local** vasoconstriction if ↑BP




In **chronic** hypertension, graph shifts to the **right** to prevent organ injury from intermittent high BP

# Phases of systemic BP regulation




**In short-term (<1 d)**  
- Baroreceptors, autonomic (SNS & PNS), vasoconstrictors are dominant



**In later phase (>1 d)**  
- Renal regulation becomes dominant in determining BP from **volume control** (via **total sodium regulation** mainly)

# Concept of pressure natriuresis




Change in BP in normal status (blue curve) is relatively **constant** despite increased salt intake (measured as urinary salt output)


**Kidney** can secrete amount of salt in response to increased BP (expanded extracellular volume) and **normalized BP** in long-term phase

**To maintain abnormal elevated BP (hypertension), dysfunction of pressure natriuresis system is proposed as a main mechanism**


# Pressure natriuresis: simplified



# Renin-Angiotensin-Aldosterone



# Current hypertension mechanisms



**Hypertension** is a complex condition caused by **genetic** susceptibility and **acquired** conditions (environmental, life-style, socio-economic, aging, drugs/diet)

+

**Abnormal body homeostasis** (regulations)

- **Renal** (impaired pressure natriuresis)
- **Vascular** (stiffness, endothelial dysfunction)
- **Neuro-hormonal** (SNS, RAAS, Sex hormones, endothelin, NO)
- **Immune** (innate + adaptive)

# What is hypertension?

- **Traditional (& convenient) criteria = Persistent office systemic arterial blood pressure  $\geq 140/90$  mmHg**
- However, data suggest risk (CV events)  $\uparrow$  starting from BP  $\geq 115/75$  mmHg
- New concept, risk of elevated BP is a continuous data (not dichotomous) and should be based on patient own CV risk (emphasis on individualization)

# Causes of hypertension

- **Primary (essential) hypertension**
- **Secondary hypertension (hypertension with specific  $\pm$  correctable cause)**
- **Genetic hypertension (identified mostly monogenic form of hypertension)**
- **Drug-induced hypertension**

**Patient can have >1 causes of hypertension combined**

# Genetic hypertension

- Hypertension has some genetic predisposing  $\approx 30\%$  but **most essential hypertension is “polygenic” and need other risk combined** (environmental, etc.)
- **Genetic hypertension** implies **monogenic** form of hypertension mostly from **abnormal renal sodium reabsorption** which is very rare in population
- Should be suspected in ***pediatrics* onset, strong family history & abnormal electrolytes**

# Monogenic hypertension

Diseases (inheritance)	Mechanisms	Unique features & treatment
<b>Hypertension with <u>hypokalemia</u></b>		
<b>High PAC, low PRA (1° hyperaldosteronism)</b>		
<b>FH type 1 (AD); GRA</b>	Chimeric CYP11B1/CYP11B2, ACTH can stimulate Ald	Hemorrhagic stroke, ↑ 18-hydroxycortisol and 18-oxocortisol, Tx and Dx with Dexa
<b>Low PAC, low PRA</b>		
<b>Liddle syndrome (AD)</b>	Mutation of β/γ subunit of PY motif of ENaC (↓ degradation of ENaC by ↓ binding of NEDD4 to PY motif)	No response to spironolactone, Tx: amiloride
AME (AR)	11β-HSD2 dysfunction, ↑ available cortisol to MR (reduced conversion of cortisol to cortisone at kidney)	Urine free Cortisol/cortisone > 5, growth retard, <b>nephrocalcinosis &amp; cyst</b> , CKD, Tx: KT, MRA, Dexa
CAH; 11β-hydroxylase def (AR)	CYP11B1 ↓: ↑ deoxycorticosterone (DOC) & androgen	XY: precocious puberty, XX: virilization
CAH; 17α-hydroxylase def (AR)	CYP17A1 ↓: ↑ DOC, ↓ sex steroids (testos, proges)	XY: ambiguous/phenotypic female, XX: 1° amen
Geller syndrome (AD)	Overactivity of mineralocorticoid receptors (aggravated by progesterone)	Aggravated by pregnancy & spironolactone, Tx: amiloride
<b>Hypertension with <u>hyperkalemia</u></b>		
<b>Gordon syndrome (pseudo hypoaldosteronism type 2) (AD)</b>	WNK1, WNK4, KLHL3, CUL3 mutation result in ↑NCC	<b>Hyperkalemic</b> , normal gap metabolic acidosis, hypercalciuria

# Secondary hypertension

- **Renal cause**
  - Renal parenchyma & Renal vascular disease
- **Cardiovascular cause**
- **Endocrine cause**
- **Miscellaneous**
  - OSA (Maybe most common cause)
  - HT in pregnancy (gestational/pre-eclampsia)
  - Obesity (mostly associate with other concomitant risk)

# Secondary hypertension

Causes	Characteristics
<b>Renal causes</b>	
Renal parenchyma*	Edema, proteinuria, hematuria, azotemia (IgAN, LN, ADPKD, etc.)
Renal vascular disease	Abdominal bruit, flash pulmonary edema, intolerant to RASi (FMD, Atherosclerosis)
<b>Cardiovascular cause</b>	
Coarctation of aorta	Arm BP > leg BP 20mmHg ( $\pm$ interarm difference), radio-femoral pulse delay (Turner)
<b>Endocrine causes</b>	
Primary aldosteronism*	Hypokalemia, resistant hypertension, adrenal incidentaloma, AF, OSA
Thyroid dysfunction	Isolated systolic HT in hyperthyroid, isolated diastolic HT in hypothyroid
1° Hyperparathyroidism	Hypercalcemia, unexplained osteoporosis, renal stones
Acromegaly	Enlarge nose, lips, tongue, hands, jaws, prognathism, OSA
Cushing syndrome	Cushingoid facies, proximal muscle weakness, thin skin, purplish striae
Pheochromocytoma	Paroxysm (spells of palpitation, sweating, headache), Orthostatic hypotension
<b>Miscellaneous</b>	
Obstructive sleep apnea*	Loud snoring/apnea/gasping, daytime sleepiness, crowded oropharynx

\*Common causes

# Secondary hypertension

Causes	Investigation
<b>Renal causes</b>	
Renal parenchyma*	Kidney biopsy, Imaging (ADPKD), specific serology test
Renal vascular disease	Doppler ultrasonography of renal artery, CTA/MRA, Catheter angiography
<b>Cardiovascular cause</b>	
Coarctation of aorta	CXR, Echocardiography, CTA
<b>Endocrine causes</b>	
Primary aldosteronism*	Plasma aldosterone concentration & Plasma renin activity
Thyroid dysfunction	Thyroid function test, specific thyroid antibody
1° Hyperparathyroidism	Calcium, Phosphate, intact Parathyroid, Film bone
Acromegaly	Serum IGF-1, GH level after OGTT
Cushing syndrome	24h-urinary free cortisol, low-dose dexamethasone suppression test, salivary cortisol
Pheochromocytoma	24h-urine fractionated metanephrine, plasma-free metanephrine
<b>Miscellaneous</b>	
Obstructive sleep apnea*	Screening: STOP-BANG/Berlin questionnaire, Diagnosis: Polysomnography

\*Common causes

# Drug-induced (exacerbating) HT

Drugs	Characteristics
<b>NSAIDs*</b>	Hyperkalemia, edema, hyponatremia, azotemia, ↓RASi efficacy
<b>Acetaminophen</b>	If taking >4 g/d
<b>Contraceptive drugs*</b>	Mostly from estrogen containing (>50 ug) pill
<b>Corticosteroids</b>	Low BP effect in low mineralocorticoids activity (dexamethasone, budesonide)
<b>Performance enhancing drug</b>	Testosterone, growth hormone, erythropoietin
<b>Herbs</b>	Licorice (>50 g in 2 weeks)
<b>Sympathomimetics*</b>	Weight loss drug, ADHD treatment, amphetamine, cocaine, ecstasy, decongestants
<b>Immunosuppression</b>	Calcineurin inhibitors (Cyclosporin A > Tacrolimus)
<b>Anti-Cancer therapy</b>	Anti-VEGF, TKIs, Gemcitabine
<b>Anti-migraine</b>	Ergots, Triptans
<b>Anti-depressants/psychiatric</b>	SSNRIs, MAOIs, lithium, carbamazepine, clozapine
<b>Miscellaneous</b>	Anti-retroviral drugs (PIs), caffeinated drinks

\*Common drugs

# Definitions

- **Hypertension:** persistent (standard) ***office*** BP  $\geq 140/90$  mmHg (adult), pediatrics (1-13y):  $\geq 95^{\text{th}}$  percentile + 12 mmHg or  $\geq 130/80$  mmHg
- **Out-of-office BP**
  - **Ambulatory BP monitoring (ABPM):**  $\geq 24$ h period (q20-30 mins)
  - **Home blood pressure monitoring (HBPM):** patient self-BP measurement from validated machine
- **White coat effect, White coat hypertension:** office BP > out-of-office BP (white coat HT = met criteria for office BP but not out-of-office BP)
- **Masked hypertension:** normal criteria for office BP but met criteria for “out-of-office” BP
- **Orthostatic hypotension:** BP after supine 5 mins then stand up then BP at 1 and 3 mins if BP  $\downarrow \geq 20/10$  mmHg (stand up from sitting is acceptable)

# Hypertension mediated organ damages

## Acute (hypertensive emergency)

Acute Stroke (ischemic/hemorrhage)



Hypertensive encephalopathy  
Posterior Reversible Encephalopathy Syndrome

Hypertensive retinopathy gr III, IV



Acute heart failure/Flash pulmonary edema

Acute coronary syndrome



Aortic dissection

AKI (Malignant HT induced TMA)



Microangiopathic hemolytic anemia (MAHA)



## Chronic

Dementia, vascular dementia

Hypertensive retinopathy gr I, II

Carotid stenosis


Left ventricular hypertrophy

Diastolic heart failure

Chronic coronary syndrome

Hypertensive nephrosclerosis (CKD)

Peripheral arterial disease



# Blood pressure measurements (office)

- **Standard office blood pressure**
  - Recommended method to **lessen white coat effect**
  - Auscultatory (mercury/aneroid) vs Automated (oscillometric)
- **Unattended standard office blood pressure**
  - Automated BP measurement **without physician** in the same room (< standard office BP  $\approx$  5-10 mmHg approximates daytime ambulatory BP)
  - Inconvenient in usual practice (only in clinical trial)

**In nowadays, automated standard office blood pressure is favored but should be validated + avoid in patient with atrial fibrillation**

# Standard measurement




**Auscultatory (manual) BP measurement  
(Mercury sphygmomanometer)**

## Preparation

- Patient avoid coffee/alcohol/smoking >30 mins
- Empty bladder
- Quiet environment, no talking (physician & patient)
- Rest (sit) for 5 minutes, back & arm support
- Both feet flat on the ground, avoid leg crossed
- Cuff at the same level of patient heart
- No cloth covered between cuff (avoid rolling up sleeves)
- Avoid muscle tensing/hand clenching

# Standard measurement




ARM CIRCUMFERENCE (CM)	USUAL CUFF SIZE
22–26	Small adult
27–34	Adult
35–44	Large adult
45–52	Adult thigh

**If cuff too small = falsely elevated BP and vice versa**

## Cuff size & place

- Bladder length is 80% of arm circumference & 40% width of arm circumference
- Place around upper arm (2 cm lower border above cubital fossa)
- Avoid same side of AV access & history of lymphedema post surgery
- First time measuring: both arms and choose the **higher one** for further measurement
- If interarm difference >20/10 mmHg, highly suspect of vasculopathy
- Remove the air in bladder (flatten) before blowing cuff


# Standard measurement



## Measurement steps

- Blow the cuff while palpating the brachial pulse for approximate the systolic BP (BP when pulse disappeared) then wait for 1 minute
- Place stethoscope on brachial artery (not between the cuff and skin)
- Blow the cuff higher 20 mmHg than the approximated BP
- Then slowly deflate the cuff 2-3 mmHg/sec
- The first sound appearing = Korotkoff 1 = SBP
- Deflating until the sound disappear = Korotkoff 5 = Diastolic blood pressure
- Repeat the entire procedure next 1 minute
- At least 3 times use the average of the last 2 only if the BP difference is <10 mmHg

# Standard measurement (automated)



**Automated method**

- Validated upper arm automated device
- The oscillometric method will measure **mean arterial pressure** but the machine will **calculate SBP & DBP**
- Cuff selection as auscultatory method
- Same patient preparation
- If atrial fibrillation (irregular rhythm), auscultatory method is preferred

# Out-of-office BP monitoring

## Home BP

- **Validated** BP device ([www.validatebp.org](http://www.validatebp.org))
- **Morning** (prior to breakfast and medicine) 2 measures and **bedtime** 2 measures for 7 days before doctor visit, use the average BP
- Same method as office BP

## Ambulatory BP

- Device **automatically** measured q 20 min during **daytime** and 30 min during **night-time** for  $\geq 24$ h
- Can detect night-time BP and dipping status
- Gold standard but not widely available

# When to consider “out-of-office BP”

- **Currently, should always be done initially to confirm hypertension** (office BP prone to error from white coat effect and correlate better with outcomes)
- Diagnosis of white coat HT & masked HT
- Improve patient adherence & participation (Home BP)
- Night-time reading (Ambulatory BP)
- Detect dipping status (poor outcome in non-dipper)

# Criteria of various BP measurement

	Office BP (mmHg) <sup>a</sup>	Home BP (mmHg)	Daytime ABPM (mmHg)	24 h ABPM (mmHg)	Night-time ABPM (mmHg)
<b>Reference</b>					
Non-elevated BP	<120/70	<120/70	<120/70	<115/65	<110/60
Elevated BP	120/70–<140/90	120/70–<135/85	120/70–<135/85	115/65–<130/80	110/60–<120/70
Hypertension	≥140/90	≥135/85	≥135/85	≥130/80	≥120/70

**For hypertension diagnosis comparing with office BP, HBPM  $\downarrow$ 5 mmHg, ABPM  $\downarrow$ 10 mmHg due to elimination of white coat effect**

# Criteria & severity of hypertension



Diagnosis	Cut off BP (mmHg)	
	SBP	DBP
Optimal	<120	<80
Normal	120-129	<80
BP at risk	130-139	80-89
Hypertension grade 1	140-159	90-99
Hypertension grade 2	160-179	100-109
Hypertension grade 3	≥180	≥110
Isolated systolic hypertension	≥140	<90
Isolated diastolic hypertension	<140	≥90

**Office BP measurement is the reference for severity grading**

# Diagnostic approach for hypertension



- 1) If grade 3 hypertension = diagnosis
- 2) If BP at risk (office) check HMOD, CVD, T2D, 10-year CV risk >10% = diagnosis
- 3) If office BP  $\geq 130/80$  mmHg and not compatible with 1,2 then confirm with “out-of-office BP” if not available then repeat standard office BP
- 4) If discordance of “office” and “out-of-office” BP use out-of-office BP

# Principle of hypertension assessment\*

- 1) Confirmation of BP for correct diagnosis
- 2) Clinical features of specific cause of HT (2°HT)
- 3) Identify comorbid (↑CV risk or affect treatment)
- 4) Patient preferences & life-style factor
- 5) Evaluation of hypertension mediated organ damage
- 6) Shared decision making of treatment plan

\*Assessment including comprehensive history taking, physical examination, and investigation

# Clinical assessment: history

- **Age of onset, previous measurement, treatment, and control**
- **Clues of 2°HT** (thyroid dysfunction, cramp/proximal muscle weakness (hypokalemia), tinnitus (FMD), paroxysm, etc.)
- **HMODs: ASCVD symptoms** (stroke, HF, CAD, PAD), **CKD** (previous renal function, nocturia, edema, etc.), **AF** (syncope/palpitation)
- **Family history, medication** (current drug & drug allergy)
- **Comorbid, personal history** (life-style; alcohol, smoking, recreational drug, salt intake, physical activity, obstetric history, LMP if reproductive age), **past-history**
- **Health coverage, occupation, domicile**

# Clinical assessment: physical examination

- **Standard BP measurement** (if initial evaluation include both arms and legs), **BP supine + upright** (look for orthostatic hypotension in initial evaluation or history of syncope upon standing), **pulse** (regularity, look for atrial fibrillation)
- **Weight & height (BMI) + waist circumference** (metabolic syndrome/obesity)
- **Clues of 2° HT** (thyroid gland enlargement, signs of hypo/hyperthyroid, neck circumference (OSA), cushingoid appearance, abdominal bruit (renal artery stenosis), proximal muscle weakness (hypokalemia), bimanual palpation (ADPKD))


# Clinical assessment: physical examination

- **HMODs: fundoscopy, carotid bruit, signs of HF** (elevated JVP, crepitation, edema, S3/S4 gallop), **LV heaving**/Apical displacement, **ABI** (ankle-brachial index; ↓ if PAD), focal **neurological deficit** (previous stroke)
- **Comorbid:** acanthosis nigricans (insulin resistance), nutrition status (malnutrition), frailty (elderly patient), reactive airway disease (contra-indication for non-selective beta blockers)

# Hypertensive retinopathy

Keith–Wagener–Baker system (1939) <sup>121</sup>		Mitchell-Wong system (2004) <sup>155</sup>		Key pathophysiological changes and signs	
Grade	Clinical features	Grade	Clinical features		
1	Mild to moderate narrowing or sclerosis of the arterioles	Mild	Generalized arteriolar narrowing, focal arteriolar narrowing, arteriovenous nicking, opacification of the arteriolar wall (silver or copper wiring), or a combination of these signs	Retinal vascular re-modelling and retinal arteriolar wall signs	} <b>Chronic</b>
2	Moderate to marked narrowing of the arterioles, local and/or generalized narrowing of arterioles, exaggeration of the light reflex, arteriovenous crossing changes or nicking				
3	Retinal arteriolar narrowing and focal constriction, retinal oedema, cotton-wool patches, retinal haemorrhages, hard exudates	Moderate	Signs of mild retinopathy plus retinal haemorrhages (blot, dot or flame-shaped), microaneurysms, cotton-wool spots, hard exudates, or a combination of these signs	Retinal tissue damage with breakdown of the blood–retina barrier and retinal microvascular signs	} <b>Acute &amp; Severe</b>
4	Grade 3 plus optic disc swelling	Malignant	Signs of moderate retinopathy plus optic disc oedema, in the presence of severely elevated blood pressure		

# Hypertensive retinopathy



# Clinical assessment: *routine* investigation


Investigation	Details
<b>Serum Cr (eGFR), UA, ACR</b>	Assessment of HMODs to kidney, Renal parenchyma as a 2° HT
<b>Electrolytes</b>	Hypernatremia (r/o 1° aldosteronism), Hyponatremia (r/o thiazide diuretics effect), Hypokalemic metabolic alkalosis (hyperaldosteronism or apparent mineralocorticoid excess), Hyperkalemia (S/E of RASi or Gordon disease)
<b>Serum calcium</b>	Hypercalcemia if 1° hyperparathyroidism
<b>Hb/HCT</b>	Erythrocytosis (severe OSA/smoking)
<b>ECG</b>	LVH (HMODs), Atrial fibrillation
<b>TSH</b>	Thyroid dysfunction as a cause of 2° HT
<b>FPG, HbA1C</b>	Metabolic syndrome or diabetes mellitus
<b>Lipid profile</b>	Dyslipidemia & calculate CV risk

ACR; urine Albumin-creatinine ratio, HMODs; hypertensive mediated organ damages, LVH; left ventricular hypertrophy

# Management of hypertension: principle

- **Treat “specific” causes** a.k.a. 2° hypertension including drug-induced HT
- **Set goal of treatment** (BP goal) based on age, frailty ( $\approx$ life expectancy), **CV risk**, side effect or tolerability
- Treatment should always **combine life-style modification & pharmacologic** treatment
- **Patient aspect** (adherence & side effect) should be monitored regularly
- Most important goal is to **↑Survival & ↓CV events** more than just blood pressure reduction

# When to consider secondary hypertension



## Extreme age of onset

Pediatrics: genetic HT

Elderly: renal artery stenosis (atherosclerosis)



## Difficult/Severe case

Resistant hypertension

Severe hypertension

Disproportionated BP and HMODs

Abruptly worsening



## Abnormal unusual findings

Hypokalemia (with/without diuretics)

Severe Obesity (obstructive sleep apnea)

Paroxysm (palpitation, sweating, headache): pheochromocytoma

Abnormal physical examinations


(cushingoid, hypo/hyperthyroid, acromegaly, abdominal bruit)

# Cause-specific treatment (example)

- **Withdrawal of drug-induced HT**
- **Anti-thyroid drugs if hyperthyroidism**
- **Termination of pregnancy if severe pre-eclampsia**
- **Unilateral laparoscopic adrenalectomy of aldosterone producing adenoma**

**Correction of hypertension causes substantially improves BP and disease specific morbidity (but not always cure HT)**

# Renovascular disease: definitions



**RVH:** arterial hypertension induced by significantly reduced renal perfusion

**Ischemic Nephropathy:** *Kidney dysfunction* from significant reduced renal perfusion

\*Not all renal artery stenosis results in RVH/Ischemic nephropathy

# Etiology

## Causes of renal artery stenosis

*Atherosclerosis renal artery stenosis (80-90%)*

*Fibromuscular disease (10%)*

Coarctation of Aorta

**Systemic vasculitis** (Takayasu arteritis, **polyarteritis nodosa**)

Renal compression (tumor, Page kidney)

Covering of origin of RA by aortic stent graft

Arteriovenous fistula

Renal artery embolism/infarction

NF-1, TSC, Ehlers–Danlos syndrome, Marfan syndrome, Turner syndrome


# Atherosclerosis-RVD vs FMD

Characteristics	ARVD	FMD
Age	> 60 years	< 40 years
Sex	Either	Female
Atherosclerosis risk	High	Normal
Extra-renal	*HF/MI/PAD	Pulsatile tinnitus 33%/headache 70% (migraine 30%)/stroke/SCAD
Lateralization	Uni/bilateral	Mostly unilateral
Renal function	Impaired	Preserved
Prognosis after revas.	+/- & may recurrent	Good & low recurrent
Lesion location	Ostium/proximal part	Middle to distal
Progression	Probably	Usually no (except dissection/aneurysm)

# Pathophysiology of hypertension

## One clip two kidneys

### UNILATERAL RENAL ARTERY STENOSIS



Reduced renal perfusion

↑ Renin angiotensin system (RAS)  
↑ Renin  
↑ Angiotensin II  
↑ Aldosterone

Angiotensin II-dependent hypertension

Increased renal perfusion


Suppressed RAS    Increased Na<sup>+</sup> excretion  
(pressure natriuresis)



**Preserved GFR**  
**High renin activity**  
**Angiotensin dependent HT**

## One clip one kidney

### BILATERAL RENAL ARTERY STENOSIS



Bilateral

Stenosis of solitary kidney

Reduced renal perfusion

↑ Renin angiotensin system (RAS)  
↑ Renin  
↑ Angiotensin II  
↑ Aldosterone

Normal or low angiotensin II

Impaired Na<sup>+</sup> and water excretion

Volume expansion

Increased arterial pressure

Inhibit RAS



**Reduced GFR**  
**Normal/low renin**  
**Salt-sensitive HT**

# Clinical manifestation

## When to suspect renovascular disease (signs and symptoms)

Early (< 30 years) or late (> 60 years) onset hypertension, in FMD and ARVD respectively

***Uncontrolled/severe resistant hypertension (40%)***

Accelerated HT of previous controlled HT within a year (24%)

***Flash pulmonary edema (Pickering syndrome)\* (up to 40%)***

***Refractory heart failure (preserved EF + LVH; diastolic dysfunction)\****


Pulsatile tinnitus & migraine headache (FMD)

***Abdominal bruit (46%)***

Angina without significant coronary artery disease in hypertensive patients

**\*Bilateral disease/unilateral in solitary functioning kidney**

# Abdominal bruits



- **Listen before palpation**
- **Aorta = Midline** (level between umbilicus and xyphoid process)
- **Renal artery = 2 cm** from midline (level between umbilicus and xyphoid process)
- **Bruits** in both systole and diastole indicate **stenosis**

**However, absence of bruit does not exclude renal artery stenosis**

# Clinical manifestation

## When to suspect renovascular disease (investigation)

Hypokalemia (16%)

Acute renal failure during treatment of hypertension

Progressive renal failure (unexplained-subnephrotic bland sediment)\*

Renal asymmetry >1.5 cm

***Increased in serum creatinine > 20-30% after RAASi within 1-2 weeks (up to 70%)\****

± High renin-high aldosterone (multiple-confounding)

**\*Bilateral disease/unilateral in solitary functioning kidney**

# Diagnosis & Treatment

- **Doppler ultrasonography** of renal artery is the 1<sup>st</sup> line screening test
- Confirmation test is “**catheter angiography**” which demonstrates significant renal artery stenosis
- **Revascularization** for significant stenosis in patient with refractory HT, recurrent HF, progressive GFR decline, bilateral disease (or solitary kidney)
- Anti-hypertensive of choice = **ACEI/ARBs** but with closed monitoring

# General management of hypertension

- **High cardiovascular risk** = Established ASCVD, Diabetes, Moderate-advance CKD, 10-year CVD risk >10%, Familial hypercholesterolemia
- **Moderate risk** = 10-year CVD risk 5-10%
- **Risk modifiers** = Autoimmune disease (SLE, Rheumatoid arthritis, etc.), HIV, Family history of premature ASCVD (male <55 y, female <65y), history of GDM/gestational HT

ASCVD; Atherosclerotic Cardiovascular Disease

**Those with High CV risk or moderate risk + risk modifiers may benefit from “more aggressive BP management”**



# Threshold of pharmacologic treatment

- Those with high CV risk: start anti-hypertensive agents if “office” **BP  $\geq 130/80$  mmHg**
- Those without risk: start anti-hypertensive agents if “office” **BP  $\geq 140/90$  mmHg**

# Goal of treatment

Age (y)	<u>Office</u> BP goal (mmHg)	<u>Home</u> BP goal (mmHg)
18-79	<130/80	<125/75 if high risk or age<65 y
65-79 with isolated systolic HT	SBP 130-139 (if tolerated)	<135/85 or history of stroke
≥80	SBP 130-139 (if tolerated)	<140/80

**Standard office BP <120/70 mmHg should be avoided  
If goal BP is intolerable, BP should be set as low as patient can get**

# Life-style modification

Categories	Details
<b>Sodium intake</b>	Limit Na <2 g/d (NaCl <5 g/d) ≈ 1 tablespoon of salt
<b>Potassium intake</b>	Moderate potassium intake 3.5-5 g/d (avoid if Hx of hyperkalemia or advanced CKD)
<b>Healthy diet</b>	DASH diet (diet rich in fruits, vegetables, whole grains, and low-fat dairy products, with reduced content of saturated and total fat)
<b>Physical activity</b>	Moderate intensity exercise 150 min/week, avoid sedentary lifestyle
<b>Optimize weight</b>	Maintain healthy BMI (18.5-22.9 kg/m <sup>2</sup> )
<b>Smoking</b>	Avoid smoking or e-cigarette
<b>Alcohol</b>	Avoid excessive alcohol (≤2 drinks in male, ≤ drink in female)
<b>Stress control</b>	Meditation, breath control, avoid pollution (noise & air)

DASH diet; Dietary Approaches to Stop Hypertension

# Pharmacologic treatment of hypertension

- Selecting anti-hypertensive agents should be based on **“compelling indication”** first
- If no preference of specific drug, then selecting class of medication in the **“first-line”** anti-hypertensive agents (**ACEIs, ARBs, DHP-CCBs, Thiazides**)
- **Avoid** combining ACEIs & ARBs
- Most patients need  $\geq 2$  classes of drugs, most effective method is **“single-pill combination”**

# Compelling indication

Conditions	Specific anti-hypertensive agents
<b>Chronic stable angina</b>	Beta-blockers, calcium channel blockers
<b>Post-MI</b>	Beta-blockers
<b>Atrial fibrillation</b>	Beta-blockers, non-DHP CCBs
<b>Heart failure (reduced EF)</b>	Beta-blockers, ACEIs/ARBs, MRAs
<b>CKD with albuminuria</b>	ACEIs/ARBs
<b>T2D (esp. CKD)</b>	ACEIs/ARBs
<b>Pregnancy</b>	Methyldopa, nifedipine, labetalol, hydralazine

MRAs; mineralocorticoid receptor antagonists (spironolactone)

# Anti-hypertensive agents

Medication class	Examples	Indications	Contra-indications	Adverse effect	Pregnancy
<b>Angiotensin converting enzyme inhibitors (ACEIs)</b>	Enalapril, -pril	Albuminuric CKD, HFrEF	Uncontrolled hyperkalemia, AKI	Hyperkalemia, GFR↓, cough, angioedema	X
<b>Angiotensin II receptor blockers (ARBs)</b>	Losartan, -sartan	Albuminuric CKD, HFrEF	Uncontrolled hyperkalemia, AKI	Hyperkalemia, GFR↓	X
<b>Dihydropyridine calcium channel blockers</b>	Amlodipine, -dipine	Chronic stable angina	HFrEF	Edema, gum hyperplasia	Nifedipine✓
<b>Thiazide/Thiazide-like</b>	Hydrochlorothiazide	Renal stones from hypercalciuria	Hyponatremia, hypokalemia	Hyponatremia, ↑Uric, ↑FPG, hypokalemia	X
<b>Beta blockers</b>	Carvedilol, -lol	HFrEF, AF, angina, post-MI	Reactive airway disease (non-specific)	Bradycardia	Labetalol✓
<b>Mineralocorticoid receptor antagonists</b>	Spironolactone	Resistant HT, Primary aldosteronism	Uncontrolled hyperkalemia, advanced CKD	Hyperkalemia, gynecomastia, ↓libido	X
<b>Alpha blockers</b>	Doxazosin, -osin	BPH, pheochromocytoma	-	Orthostatic hypotension	X

# Resistant hypertension: definition

- Hypertension that after treatment strategy including appropriate lifestyle measures and treatment with maximum or maximally tolerated doses of a diuretic (thiazide or thiazide-like), a **RAS blocker**, and a **calcium channel blocker** fail to lower office BP <140/90 mmHg which is **confirmed by “out-of-office”** BP measurement

**Pseudo-resistant HT should be excluded (non-adherence)  
If advanced CKD (GFR <30 ml/min), adequate loop diuretics dose should be attempted**

\*Refractory HT = BP not in target despite ≥5 medications, including spironolactone, long-acting thiazide like diuretics

# Resistant hypertension management

- **Confirm** out-of-office BP & adherence
- R/O **drug-induced** HT & **secondary** HT
- **Refer** to specialist (cardiologist or nephrologist)
- If GFR > 30 mL/min add **spironolactone**
- If GFR < 30 mL/min add **long-acting thiazide-like** diuretic




If BP goal not met

Add Beta blockers, convert RAS blockers to ARNI\*  
 If GFR > 30 mL/min, consider renal denervation

\*ARNI, Angiotensin Receptor-Neprilysin Inhibitors

# Hypertensive emergency: evaluation

- Hypertensive emergency = severe HT (mostly grade III;  $\geq 180/110$  mmHg) with acute hypertension mediated organ damage



## Causes

- Poor adherence (mostly essential HT)
- 2° HT should be look for

# Hypertensive emergency: management

- Admit ICU + invasive BP monitoring + IV short-acting anti-hypertensive agents
- Target BP lowering & class of drug depends on organ involvement
- Consult specialists + organ support

Organ involvement	Target BP (mmHg)	Anti-hypertensive agents
ACS/acute HF	SBP <140 as fast as possible	Nitroglycerine, furosemide (if HF)
Aortic dissection	SBP <120, pulse <60/min as fast as possible	Labetalol, esmolol, nicardipine
Ischemic stroke	If re-perfusion treatment: <180/105 for 1 d If no re-perfusion: <220/110, ↓15% in 1d	Nicardipine, labetalol
Hemorrhagic stroke	SBP 140-160 within 6 h of symptoms	Nicardipine, labetalol
Malignant HT (hypertensive retinopathy gr III/IV), TMA	SBP ↓25% within the 1 <sup>st</sup> h then <160/100 in next 2-6h then SBP 130-140 in next 1-2 d	Nicardipine, labetalol, nitroprusside (avoid if AKI)
Severe pre-eclampsia/eclampsia	<160/105 within 150-180 min	Labetalol, nifedipine, methyldopa

# Take home message

- **Hypertension is very common and remains the most important systemic disease involving multiple organs**
- **Screening and making correct diagnosis by standard BP measurement is the essential step**
- **Comprehensive assessment is crucial**
- **Always identify treatable causes**
- **Treatment including life-style modification + drugs**



NEPHROLOGY  
PHRAMONGKUTKLAO HOSPITAL



**Thank you for your attention**